Several amphetamines, many of which are popular illicit drugs of abuse, produce long-term neurotoxicity to dopaminergic and/or serotonergic neurons in experimental animals. Interestingly, the type of monoaminergic neuron damaged depends on both the analog injected as well as the species of animal used. It is not known why some amphetamines are selectively toxic to serotonergic neurons whereas others affect both systems or only dopaminergic neurons nor why the neurotoxic profile for the amphetamines differs between the mouse and rat. Furthermore, the mechanisms by which these compounds produce neurotoxicity are unknown. The amphetamines release both dopamine (DA) and serotonin (5HT) and it has been hypothesized that oxygen-derived products resulting from the oxidation of these monoamines may be the toxic species. Additionally, methamphetamine-induced damage to dopaminergic neurons can be prevented by antagonists of the N-methyl-D-aspartate (NMDA) receptor, one of the subtypes of the glutamate receptor. These findings indicate that an excitotoxic mechanism may be involved in the neurotoxic process. The hypothesis to be tested is that the facilitated release of the monoamines by the amphetamines leads to free radical generation and a release of excitatory amino acids which results in a tremendous increase in oxidative stress in dopaminergic nerve terminals. The goal of our research is to gain a better understanding of amphetamine-induced neuropathology.
The aims of the proposed studies are 1) to characterize and investigate reasons for the differential neurotoxicity of various amphetamines on monoaminergic neurons in both mice and rats, 2) to further evaluate the involvement of the excitatory amino acids and oxidative stress in amphetamines-induced toxicity to monoaminergic neurons and 3) to determine the extent to which DA and 5HT release produced by the various amphetamines contributes to dopaminergic or serotonergic toxicity.. The studies will be conducted in mice and rats. Characterizing the species differences should help to delineate the mechanisms underlying neurotoxicity. Biochemical techniques and pharmacological agents will be used to study the effects of the amphetamines. An understanding of the mechanisms by which the amphetamines damage monoaminergic neurons has important implications not only for amphetamine abuse but for disorders of unknown etiology such as Parkinson's Disease, schizophrenia and depression in which there are abnormalities in dopaminergic and serotonergic function.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA006236-06
Application #
2118546
Study Section
Special Emphasis Panel (SRCD (06))
Project Start
1990-03-01
Project End
1997-03-31
Budget Start
1995-04-01
Budget End
1996-03-31
Support Year
6
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of Medicine & Dentistry of NJ
Department
Neurology
Type
Schools of Medicine
DUNS #
622146454
City
Piscataway
State
NJ
Country
United States
Zip Code
08854
Gluck, M R; Moy, L Y; Jayatilleke, E et al. (2001) Parallel increases in lipid and protein oxidative markers in several mouse brain regions after methamphetamine treatment. J Neurochem 79:152-60
Hogan, K A; Staal, R G; Sonsalla, P K (2000) Analysis of VMAT2 binding after methamphetamine or MPTP treatment: disparity between homogenates and vesicle preparations. J Neurochem 74:2217-20
Moy, L Y; Albers, D S; Sonsalla, P K (1998) Lowering ambient or core body temperature elevates striatal MPP+ levels and enhances toxicity to dopamine neurons in MPTP-treated mice. Brain Res 790:264-9
Albers, D S; Zeevalk, G D; Sonsalla, P K (1996) Damage to dopaminergic nerve terminals in mice by combined treatment of intrastriatal malonate with systemic methamphetamine or MPTP. Brain Res 718:217-20
Albers, D S; Sonsalla, P K (1995) Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents. J Pharmacol Exp Ther 275:1104-14
Delle Donne, K T; Sonsalla, P K (1994) Protection against methamphetamine-induced neurotoxicity to neostriatal dopaminergic neurons by adenosine receptor activation. J Pharmacol Exp Ther 271:1320-6
Terleckyj, I; Sonsalla, P K (1994) The sigma receptor ligand (+/-)-BMY 14802 prevents methamphetamine-induced dopaminergic neurotoxicity via interactions at dopamine receptors. J Pharmacol Exp Ther 269:44-50
Sonsalla, P K; Riordan, D E; Heikkila, R E (1991) Competitive and noncompetitive antagonists at N-methyl-D-aspartate receptors protect against methamphetamine-induced dopaminergic damage in mice. J Pharmacol Exp Ther 256:506-12